Evidence map›Paper›PMID 42609784›Full record

ArticleERJ open research2026

Add-on mepolizumab in patients with severe asthma on medium-dose inhaled corticosteroids.

Ruchong Chen, Liping Wei, Meiling Jin, Yi Jiang, Xinglin Gao, Li Zhao, Limin Wang, Shengming Liu, Peter Howarth, Cui Xiong and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03562195 (A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03562195 phase3completednot on this map

A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation

TypeinterventionalSponsorGlaxoSmithKlineRan2018 to 2022Enrolled300ConditionsAsthmaArmsMepolizumab 100 milligrams, Placebo, Salbutamol
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruchong ChenState Key Laboratory of Respiratory Disease, Joint International Research Laboratory of Respiratory Health, National Clinical Research Center for Respiratory Disease, Guangzhou National Laboratory, Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0001-5376-8230
Liping WeiDepartment of Pulmonary and Critical Care Medicine, 3rd Affiliated Hospital of Guangzhou, Guangzhou, China.
Meiling JinDepartment of Allergy and Clinical Immunology, Zhongshan Hospital Fudan University, Shanghai, China.
Yi JiangDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Shanxi Medical University, Taiyuan, China.
Xinglin GaoDepartment of Pulmonary and Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Li ZhaoDepartment of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Limin WangDepartment of Pulmonary and Critical Care Medicine, Hangzhou First People's Hospital, Hangzhou, China.
Shengming LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Peter HowarthGlobal Medical Affairs, Specialty Medicine, GSK, Brentford, UK.ORCID https://orcid.org/0000-0003-0619-7927
Cui XiongR&D, GSK, Shanghai, China.
Jie HuangMedical Affairs, GSK, Shanghai, China.
Peiwen LiangMedical Affairs, GSK, Shanghai, China.
Xiao HuMedical Affairs, GSK, Shanghai, China.
Nanshan ZhongState Key Laboratory of Respiratory Disease, Joint International Research Laboratory of Respiratory Health, National Clinical Research Center for Respiratory Disease, Guangzhou National Laboratory, Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mepolizumab is clinically beneficial for patients with severe asthma with an eosinophilic phenotype (SA-EP) but lacks randomised controlled trial efficacy data in those on medium-dose inhaled corticosteroids (ICS). This analysis assessed mepolizumab's efficacy in a subgroup of patients on medium-dose ICS from a Chinese phase 3 trial (NCT03562195). Methods: Eligible SA-EP patients had received daily ≥500 µg·day Results: At week 52, in the medium-dose ICS subgroup, mepolizumab (n=115) Conclusions: Mepolizumab provided greater clinical benefit across multiple outcomes including clinical remission

Identifiers

PMID42609784
PMCPMC13478892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.